CN103860506A - Veterinary antipyretic analgesic tablet and preparation method thereof - Google Patents
Veterinary antipyretic analgesic tablet and preparation method thereof Download PDFInfo
- Publication number
- CN103860506A CN103860506A CN201210550316.9A CN201210550316A CN103860506A CN 103860506 A CN103860506 A CN 103860506A CN 201210550316 A CN201210550316 A CN 201210550316A CN 103860506 A CN103860506 A CN 103860506A
- Authority
- CN
- China
- Prior art keywords
- tolfenamic acid
- hydroxypropyl methylcellulose
- matrix tablet
- acid matrix
- lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a tolfenamic acid matrix tablet. The tolfenamic acid matrix tablet comprises active ingredient tolfenamic acid, polymer hydroxypropyl methyl cellulose (MethocelE4M), filler and a lubricant. The sustained-release tolfenamic acid matrix tablet prepared by the method has a good drug sustained-release effect, is longer in effect time than ordinary tablets, and is low in adverse reaction. The tolfenamic acid matrix tablet has the advantages of simple preparation technology, low cost and stable product quality, and is suitable for industrialized production.
Description
Technical field
The present invention relates to a kind of tolfenamic acid matrix tablet that is used for the treatment of the arthritis such as Canis familiaris L., cat, arthritis pain and operation pain.
Background technology
Tolfenamic acid is the anthranilic acid derivative (Tolfenamic acid) by the exploitation of GEA company of Denmark, is a kind of widely used nonsteroidal anti-inflammatory drug.Its chemical name is: Tolfenamic Acid, molecular formula: C
14h
12clNO
2, molecular weight: 261.70, chemical structural formula:
Tolfenamic acid has stronger selectivity to COX-2, so have stronger anti-inflammatory and analgesic effect and less side effect.Be mainly used at present the treatment of arthritis and migraine, be also widely used in the treatment of the diseases such as gout, bursitis and dysmenorrhea.In addition also alleviate relevant inflammation and the pain of osteoarthrosis as house pet medicine for Canis familiaris L., cat, also can be used for the auxiliary treatment of the domestic animal such as pig, cattle upper respiratory disease.Tolfenamic acid has evident in efficacy, and the feature that side effect is little can be applied to people simultaneously and use and market for animals, has wide market potential.
After the oral tolfenamic acid of the animal such as dog, cat, absorb rapidly, and with higher CONCENTRATION DISTRIBUTION in liver, kidney, blood plasma.It is original shape drug level 1-2h peaking after administration in vivo, and biological half-life is shorter, needs administration frequent, and long term administration easily produces untoward reaction; In order to reduce administration number of times, we have developed tolfenamic acid matrix tablet, and this matrix tablet is take hydroxypropyl methylcellulose as framework material, take the gel barrier that rear tablet surface forms one deck stiff, the release of blocking medicine, extends tablet in the gastrointestinal holdup time, makes medicine reach the effect of controlled release.
Summary of the invention
The present invention provides a kind of tolfenamic acid matrix tablet that is used for the treatment of the arthritis such as Canis familiaris L., cat, arthritis pain and operation pain first.
An object of the present invention is to provide a kind of tolfenamic acid matrix tablet, active component is tolfenamic acid.
Another object of the present invention is to provide a kind of preparation method of described tolfenamic acid matrix tablet.
A kind of tolfenamic acid matrix tablet, it is composed as follows, weight share meter:
Tolfenamic acid: 50 parts, hydroxypropyl methylcellulose: 40-120 part, filler: 0-60 part, lubricant: 5-15 part.
In described tolfenamic acid matrix tablet, contain tolfenamic acid 25mg-75mg.
Described hydroxypropyl methylcellulose is one or more in hydroxypropyl methylcellulose E4M, hydroxypropyl methylcellulose F4M, hydroxypropyl methylcellulose K4M, hydroxypropyl methylcellulose K15M, hydroxypropyl methylcellulose K100M.
Described filler is one or more in starch, microcrystalline Cellulose, lactose, amylum pregelatinisatum, Icing Sugar, inorganic salt, mannitol.
Described lubricant is one or more in magnesium stearate, micropowder silica gel (Aerosil 200 and Aerosil 300), Pulvis Talci, Polyethylene Glycol.
Concrete preparation method of the present invention is as follows:
Principal agent and adjuvant hydroxypropyl methylcellulose, filler, lubricant are crossed to 100 mesh sieves, take recipe quantity principal agent tolfenamic acid and filler and a small amount of lubricant, mix homogeneously, adds adhesive soft material processed, the granulation of sieving, dry, granulate, adds the lubricant of surplus, mixes, be pressed into controlled release tablet, obtain final product.
Any in the starch slurry that described adhesive is water, the percent by volume ethanol water that is 5%-30%, mass percent is 1%-15%, the cellulose derivative aqueous solution that mass percentage concentration is 1%-15%, polyvidone aqueous solution that mass percentage concentration is 1%-15%, aqueous gelatin solution that mass percentage concentration is 1%-15%, Aqueous Solutions of Polyethylene Glycol that mass percentage concentration is 1%-15%.
Tolfenamic acid matrix tablet of the present invention, selects hydroxypropyl methylcellulose and microcrystalline Cellulose mixed matrix material to make tolfenamic acid matrix tablet, infers through results of stability, preserves 3 years steady qualities containing the controlled release tablet of tolfenamic acid 50mg under 25 ℃ of conditions.Show that constant product quality is good.
Tolfenamic acid matrix tablet of the present invention is used for the treatment of the arthritis such as Canis familiaris L., cat, arthritis pain and operation pain.Preparation technology of the present invention is simple, and cost is low, is suitable for suitability for industrialized production.
The specific embodiment
The embodiment that provided below, just in order to help to understand the present invention, rather than forms protection domain of the present invention is played to restrictive effect, under design prerequisite of the present invention, the present invention is simply changed, and all belongs to the scope of protection of present invention.
Embodiment 1:
Prescription composition:
Tolfenamic acid 50mg
Hydroxypropyl methylcellulose 80mg
Microcrystalline Cellulose 50mg
Magnesium stearate 7.5mg
Polyvinylpyrrolidone 7.5mg
Every total amount 200mg
Preparation method: tolfenamic acid and adjuvant hydroxypropyl methylcellulose, microcrystalline Cellulose, magnesium stearate are crossed to 100 mesh sieves, take recipe quantity principal agent tolfenamic acid and adjuvant hydroxypropyl methylcellulose, microcrystalline Cellulose and a small amount of magnesium stearate, be that adhesive is granulated with 10% polyvinylpyrrolidone aqueous solution, dry, granulate, adds the magnesium stearate of surplus, mixes, be pressed into controlled release tablet, obtain final product.
Embodiment 2:
Prescription composition:
Tolfenamic acid 50mg
Hydroxypropyl methylcellulose 80mg
Microcrystalline Cellulose 50mg
Magnesium stearate 4mg
Micropowder silica gel (Aerosil 200) 3.5mg
Polyvinylpyrrolidone 7.5mg
Every total amount 200mg
Preparation method: tolfenamic acid and adjuvant hydroxypropyl methylcellulose, microcrystalline Cellulose, magnesium stearate are crossed to 100 mesh sieves, take recipe quantity principal agent tolfenamic acid and adjuvant hydroxypropyl methylcellulose, microcrystalline Cellulose and a small amount of magnesium stearate and micropowder silica gel, be that adhesive is granulated with 10% polyvinylpyrrolidone aqueous solution, dry, granulate, adds magnesium stearate and the micropowder silica gel of surplus, mixes, be pressed into controlled release tablet, obtain final product.
Claims (6)
1. a tolfenamic acid matrix tablet, is characterized in that it contains following composition, weight share meter:
Tolfenamic acid: 50 parts
Hydroxypropyl methylcellulose: 40-120 part
Filler: 0-60 part
Lubricant: 5-15 part
According to tolfenamic acid matrix tablet claimed in claim 1, it is characterized in that containing tolfenamic acid 25mg-75mg.
2. according to tolfenamic acid matrix tablet claimed in claim 1, it is characterized in that described hydroxypropyl methylcellulose is one or more in hydroxypropyl methylcellulose E4M, hydroxypropyl methylcellulose F4M, hydroxypropyl methylcellulose K4M, hydroxypropyl methylcellulose K15M, hydroxypropyl methylcellulose K100M.
3. according to tolfenamic acid matrix tablet claimed in claim 1, it is characterized in that described filler is one or more in starch, microcrystalline Cellulose, lactose, amylum pregelatinisatum, Icing Sugar, inorganic salt, mannitol.
4. according to tolfenamic acid matrix tablet claimed in claim 1, it is characterized in that described lubricant is one or more in magnesium stearate, micropowder silica gel (Aerosil 200 and Aerosil 300), Pulvis Talci, Polyethylene Glycol.
5. according to the preparation method of tolfenamic acid matrix tablet claimed in claim 1, it is characterized in that step is as follows:
Principal agent and adjuvant hydroxypropyl methylcellulose, filler, lubricant are crossed to 100 mesh sieves, take recipe quantity principal agent tolfenamic acid and filler and a small amount of lubricant, mix homogeneously, adds adhesive soft material processed, the granulation of sieving, dry, granulate, adds the lubricant of surplus, mixes, be pressed into controlled release tablet, obtain final product.
6. according to the preparation method of tolfenamic acid matrix tablet claimed in claim 6, it is characterized in that any in described adhesive is water, the percent by volume ethanol water that is 5%-30%, mass percent is 1%-15% starch slurry, cellulose derivative aqueous solution that mass percentage concentration is 1%-15%, polyvidone aqueous solution that mass percentage concentration is 1%-15%, aqueous gelatin solution that mass percentage concentration is 1%-15%, Aqueous Solutions of Polyethylene Glycol that mass percentage concentration is 1%-15%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210550316.9A CN103860506A (en) | 2012-12-18 | 2012-12-18 | Veterinary antipyretic analgesic tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210550316.9A CN103860506A (en) | 2012-12-18 | 2012-12-18 | Veterinary antipyretic analgesic tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103860506A true CN103860506A (en) | 2014-06-18 |
Family
ID=50899899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210550316.9A Pending CN103860506A (en) | 2012-12-18 | 2012-12-18 | Veterinary antipyretic analgesic tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103860506A (en) |
-
2012
- 2012-12-18 CN CN201210550316.9A patent/CN103860506A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5465824B2 (en) | Pharmaceutical preparation and method for producing the same | |
| RU2446800C2 (en) | Controlled-release preparative forms | |
| CN101073563B (en) | Chiral composition containing dextrothyroxine buprofenli and levomethadyl cysteliqin and its double slow-releasing tablet | |
| CN101431992A (en) | Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof | |
| NZ549630A (en) | Pharmaceutical composition comprising pimobendan | |
| Shaikh et al. | Formulation and evaluation of Ibuprofen gastro-retentive floating tablets | |
| CN100534429C (en) | Laevo-ornidazole vagina administration preparation, its preparing method and use | |
| KR101479824B1 (en) | Elution-stabilized preparation | |
| KR101050076B1 (en) | Compositions of Oral Formulations Containing Controlled Release Aceclofenac and Methods for Making the Same | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| CN103520169B (en) | Mirtazapine tablet and preparation method thereof | |
| ES2197676T3 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IBUPROFEN AND DOMPERIDONA. | |
| CN108014077A (en) | Carbasalate calcium sustained release preparation and preparation method thereof | |
| CN103271890B (en) | Hydrochloric acid pramipexole capsule and preparation method thereof | |
| CN1943561A (en) | Oral disintegration tablet of prulifloxacin and its preparing method | |
| CN102100679A (en) | Carprofen matrix tablets | |
| CN103860506A (en) | Veterinary antipyretic analgesic tablet and preparation method thereof | |
| CN103083271A (en) | Analgesic tablet for pets | |
| JP2007023001A (en) | Method for stabilizing thiamine compounds | |
| JP2013163698A (en) | Pharmaceutical preparation and method for producing the same | |
| CN102641253B (en) | Valsartan sustained release tablet and preparation method thereof | |
| CN106361708A (en) | High-density micropill core and preparation method thereof | |
| CN104739794A (en) | Novel potassium citrate sustained release tablet and preparation method thereof | |
| CN100409754C (en) | Fresh keeping tablet for grape produced adopting full powder direct pelleting method | |
| CN100364519C (en) | Chewing tablet of tramado hydrochloride and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140618 |